Latest PCOS / PMOS research
Accessible summaries of recent studies — with verified sources and what it means for you.
Tirzepatide in PCOS: real-world weight loss matches women without PCOS
UK cohort of 4,241 women with self-reported PCOS: −19.4% mean body weight at 10 months, statistically no different from women without PCOS.
19 August 2026 · Clift AK et al., Journal of the Endocrine Society, 19 August 2026 (PMID 42634795)
Gestational diabetes in PCOS pregnancies: pooled prevalence 24%
Meta-analysis of 22 studies and 5,507 women with PCOS: about one pregnancy in four develops gestational diabetes; HOMA-IR is the strongest associated factor.
17 July 2026 · Yuan Y et al., Frontiers in Endocrinology, 17 July 2026 (PMID 42539429)
PCOS and breast cancer: 18 studies reviewed, association modest and still unsettled
Systematic review of 18 studies: a possible modest increase in breast cancer risk, mainly before menopause, but the evidence stays heterogeneous and inconclusive.
20 June 2026 · Costanzi F et al., European Journal of Obstetrics, Gynecology and Reproductive Biology, 20 June 2026 (PMID 42335748)
Adding tirzepatide to metformin in PCOS: first randomised results, 16 weeks
Open-label RCT in 60 overweight women with PCOS: −10.4 kg with metformin + tirzepatide 5 mg versus −1.7 kg with metformin alone, plus better cycle recovery.
3 June 2026 · Yang Z et al., Diabetes, Obesity and Metabolism, 3 June 2026 (PMID 42236268)
PERIODS: the first dedicated tirzepatide trial in PCOS is recruiting
University of Bonn, phase 4, 198 participants, placebo-controlled — primary outcome is menstrual regularity, not weight.
9 December 2025 · ClinicalTrials.gov NCT07326111 (University of Bonn), recruiting since 9 December 2025